NanoViricides Begins Patient Enrollment in Phase II Ebola Trial, Testing Oral NV-387 Gummies

NanoViricides, Inc. (NYSE American: NNVC), a clinical-stage company developing special purpose nanomaterials for antiviral therapy, has announced the initiation of patient enrollment and dosing in its Phase II clinical trial of NV-387 Oral Gummies for the treatment of Bundibugyo Ebolavirus and other Ebola viruses. The trial is taking place at an Ebola Treatment Center in the Ituri province of the Democratic Republic of Congo (DRC), a region that has experienced recurrent Ebola outbreaks. The Phase IIA portion began enrollment and dosing around September 23 and is designed to establish a safe and well-tolerated dosing protocol. The resulting protocol will then be used in the Phase IIB portion, which will evaluate safety, tolerability, and effectiveness. The trial is registered in the Pan African Clinical Trials Registry under identification number PACTR202608748555077. For investors and industry observers, this milestone represents a significant step forward for NanoViricides and its proprietary nanoviricide technology. The company’s lead drug candidate, NV-387, is being developed as a broad-spectrum antiviral with potential applications beyond Ebola, including RSV, COVID-19, Long COVID, Influenza, MPOX/Smallpox, and Measles. If successful, NV-387 could become a versatile tool in the fight against a range of viral threats, addressing unmet medical needs in both outbreak settings and endemic regions. The initiation of this trial also underscores the company’s ability to advance its pipeline into human clinical testing, a critical validation of its platform. NanoViricides has a worldwide exclusive perpetual license to the TheraCour nanomedicine technology for several human viral diseases, including HIV/AIDS, Hepatitis B and C, Rabies, Herpes Simplex, Varicella-Zoster, Influenza, Dengue, Japanese Encephalitis, West Nile, Ebola/Marburg, and certain Coronaviruses. The company’s business model is based on licensing technology from TheraCour Pharma Inc. for specific application verticals, as established at its foundation in 2005. The Phase II trial’s progress could have broader implications for global health security, as Ebola remains a high-priority pathogen with limited treatment options. The World Health Organization has classified Bundibugyo Ebolavirus as a variant of concern, and the development of an oral, broad-spectrum antiviral could simplify treatment logistics in resource-limited settings. For NanoViricides, successful trial results could pave the way for regulatory approvals and potential partnerships. The company’s other advanced drug candidate, NV-HHV-1, is in development for the treatment of Shingles. As with any drug development effort, there can be no assurance that NV-387 will show sufficient effectiveness and safety for human clinical development. The path to typical drug development is extremely lengthy and requires substantial capital. Nevertheless, the start of patient enrollment and dosing marks a tangible advance for NanoViricides and its investors. The company’s newsroom, available at https://ibn.fm/NNVC, provides the latest updates relating to NNVC. Additional information about the company can be found at www.nanoviricides.com. The full press release is available at https://ibn.fm/qC4Hk. MissionIR, a specialized communications platform, is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers access to a vast network of wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, social media distribution via IBN to millions of social media followers, and a full array of tailored corporate communications solutions.